JP5180074B2 - サイモシンβ４誘導体及びその使用方法 - Google Patents

サイモシンβ４誘導体及びその使用方法 Download PDF

Info

Publication number
JP5180074B2
JP5180074B2 JP2008520699A JP2008520699A JP5180074B2 JP 5180074 B2 JP5180074 B2 JP 5180074B2 JP 2008520699 A JP2008520699 A JP 2008520699A JP 2008520699 A JP2008520699 A JP 2008520699A JP 5180074 B2 JP5180074 B2 JP 5180074B2
Authority
JP
Japan
Prior art keywords
ala
gly
group
administration
thymosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008520699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500045A5 (https=
JP2009500045A (ja
Inventor
ニエ，リヤ
マ，スヨン
シュ，ソンシャン
ウェン，メイユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotoxtech Co Ltd
Original Assignee
Biotoxtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200510083894 external-priority patent/CN1896096A/zh
Priority claimed from CNB2005101032937A external-priority patent/CN100484957C/zh
Application filed by Biotoxtech Co Ltd filed Critical Biotoxtech Co Ltd
Publication of JP2009500045A publication Critical patent/JP2009500045A/ja
Publication of JP2009500045A5 publication Critical patent/JP2009500045A5/ja
Application granted granted Critical
Publication of JP5180074B2 publication Critical patent/JP5180074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008520699A 2005-07-15 2006-07-14 サイモシンβ４誘導体及びその使用方法 Active JP5180074B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200510083894.6 2005-07-15
CN 200510083894 CN1896096A (zh) 2005-07-15 2005-07-15 基因工程方法生产的高活性胸腺素β4衍生物
CN200510103293.7 2005-09-23
CNB2005101032937A CN100484957C (zh) 2005-09-23 2005-09-23 胸腺素β4衍生物及其应用
PCT/CN2006/001679 WO2007009359A1 (en) 2005-07-15 2006-07-14 Thymosin beta 4 derivatives and use thereof

Publications (3)

Publication Number Publication Date
JP2009500045A JP2009500045A (ja) 2009-01-08
JP2009500045A5 JP2009500045A5 (https=) 2009-07-23
JP5180074B2 true JP5180074B2 (ja) 2013-04-10

Family

ID=37668439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008520699A Active JP5180074B2 (ja) 2005-07-15 2006-07-14 サイモシンβ４誘導体及びその使用方法

Country Status (7)

Country Link
US (1) US7816321B2 (https=)
EP (1) EP1908779B1 (https=)
JP (1) JP5180074B2 (https=)
KR (1) KR100984635B1 (https=)
CN (1) CN100582121C (https=)
PL (1) PL1908779T3 (https=)
WO (1) WO2007009359A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008001084A (es) * 2005-07-26 2008-03-11 Regenerx Biopharmaceuticals Composiciones para el tratamiento o prevencion del deterioro, lesion o dano de tejido debido a insuficiencia cardiaca congestiva.
GB2476789A (en) * 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes
US9504730B2 (en) 2010-09-30 2016-11-29 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
CN103724422B (zh) * 2014-01-13 2015-10-21 哈尔滨吉象隆生物技术有限公司 一种裂解胸腺素β4的方法
CN104311672B (zh) * 2014-10-21 2017-07-11 中国药科大学 一种具有肿瘤细胞靶向性的抑制剂多肽
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
KR101946789B1 (ko) * 2018-01-26 2019-02-12 (주)휴온스 이황화결합 이성질화효소 신호 펩타이드를 포함하는 재조합 벡터 및 이의 용도
US11311606B2 (en) * 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
CN108853483B (zh) * 2018-08-10 2022-03-15 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
CN110215513B (zh) * 2018-11-15 2022-02-22 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗放射性肠炎方面的用途
CN109865127B (zh) * 2018-11-22 2022-03-04 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4395404A (en) * 1982-05-14 1983-07-26 George Washington University Synthetic thymosin β3 and β4 analogues
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US7585943B2 (en) * 2005-04-20 2009-09-08 Viromed Co., Ltd. Compositions and methods for fusion protein separation

Also Published As

Publication number Publication date
EP1908779A4 (en) 2009-09-30
US20090298758A1 (en) 2009-12-03
KR20080040708A (ko) 2008-05-08
KR100984635B1 (ko) 2010-10-01
PL1908779T3 (pl) 2013-06-28
CN101218249A (zh) 2008-07-09
JP2009500045A (ja) 2009-01-08
EP1908779A1 (en) 2008-04-09
US7816321B2 (en) 2010-10-19
EP1908779B1 (en) 2013-01-09
WO2007009359A1 (en) 2007-01-25
CN100582121C (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
EP0309100B1 (en) Use of amylin or CGRP for the treatment of diabetes mellitus
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
JP5180074B2 (ja) サイモシンβ４誘導体及びその使用方法
KR20120082909A (ko) 합성 마이오스타틴 펩티드 길항제
US11578112B2 (en) Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin
JP2016536306A (ja) ヒト・リラキシン類似体、その医薬組成物及びその医薬用途
JP4954215B2 (ja) 皮膚状態改善または歯周疾患の治療効能を有するペプチド
US20130085108A1 (en) Peptides for promoting angiogenesis and an use thereof
CN100484957C (zh) 胸腺素β4衍生物及其应用
JP7499533B2 (ja) 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
KR20210154784A (ko) 섬유질환 예방 또는 치료용 재조합 융합 단백질
KR20240086942A (ko) 연골 재생용 펩타이드 및 이의 용도
KR20240086939A (ko) 연골 재생용 펩타이드 및 이의 용도
CN112500493A (zh) 重组人神经调节蛋白衍生物及其用途
WO2005079831A1 (en) Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis
CN110577589A (zh) 胰岛素样生长因子结合蛋白4突变体及其制药用途
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090602

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130110

R150 Certificate of patent or registration of utility model

Ref document number: 5180074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250